AU2006318212C1 - Oncogenic ras-specific cytotoxic compound and methods of use thereof - Google Patents

Oncogenic ras-specific cytotoxic compound and methods of use thereof Download PDF

Info

Publication number
AU2006318212C1
AU2006318212C1 AU2006318212A AU2006318212A AU2006318212C1 AU 2006318212 C1 AU2006318212 C1 AU 2006318212C1 AU 2006318212 A AU2006318212 A AU 2006318212A AU 2006318212 A AU2006318212 A AU 2006318212A AU 2006318212 C1 AU2006318212 C1 AU 2006318212C1
Authority
AU
Australia
Prior art keywords
butyl
methyl
oncrasin
chloro
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006318212A
Other languages
English (en)
Other versions
AU2006318212A1 (en
AU2006318212B2 (en
Inventor
Bingliang Fang
Wei Guo
Jinsong Liu
Shuhong Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2006318212A1 publication Critical patent/AU2006318212A1/en
Application granted granted Critical
Publication of AU2006318212B2 publication Critical patent/AU2006318212B2/en
Publication of AU2006318212C1 publication Critical patent/AU2006318212C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006318212A 2005-11-23 2006-11-22 Oncogenic ras-specific cytotoxic compound and methods of use thereof Ceased AU2006318212C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73986505P 2005-11-23 2005-11-23
US60/739,865 2005-11-23
PCT/US2006/061219 WO2007062399A2 (en) 2005-11-23 2006-11-22 Oncogenic ras-specific cytotoxic compound and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2006318212A1 AU2006318212A1 (en) 2007-05-31
AU2006318212B2 AU2006318212B2 (en) 2012-01-12
AU2006318212C1 true AU2006318212C1 (en) 2012-08-30

Family

ID=38068056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006318212A Ceased AU2006318212C1 (en) 2005-11-23 2006-11-22 Oncogenic ras-specific cytotoxic compound and methods of use thereof

Country Status (8)

Country Link
US (1) US8883841B2 (cg-RX-API-DMAC10.html)
EP (1) EP1956910B1 (cg-RX-API-DMAC10.html)
JP (1) JP5460054B2 (cg-RX-API-DMAC10.html)
CN (1) CN101360422B (cg-RX-API-DMAC10.html)
AU (1) AU2006318212C1 (cg-RX-API-DMAC10.html)
CA (1) CA2631082C (cg-RX-API-DMAC10.html)
RU (1) RU2448703C2 (cg-RX-API-DMAC10.html)
WO (1) WO2007062399A2 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212489B1 (pl) * 2008-01-22 2012-10-31 Univ Jagiellonski Pochodne fenoksyalkiloaminoalkanoli i ich zastosowania
KR20100135248A (ko) * 2008-04-01 2010-12-24 아스텔라스세이야쿠 가부시키가이샤 인돌리논 화합물
BRPI0910198A2 (pt) * 2008-06-30 2016-01-12 Silenseed Ltd composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2011060976A1 (en) * 2009-11-20 2011-05-26 Universite De Liege Tryptamine-derived compounds as antibacterial agents
WO2011075567A1 (en) * 2009-12-16 2011-06-23 University Of New Hampshire Emulsion polymerization of esters of itaconic acid
US9526709B2 (en) 2011-04-06 2016-12-27 Chemo-Enhanced Llc Compositions and methods for treating cancer
US9474730B2 (en) * 2012-04-30 2016-10-25 Board Of Regents Of The University Of Texas System Methods and compositions for use with K-ras mediated disorders
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
US9908863B2 (en) 2013-01-10 2018-03-06 Merck Patent Gmbh Piperidinylcarbazoles
US9968570B2 (en) 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
EP3148981A4 (en) * 2014-05-30 2017-11-08 The Trustees of Columbia University in the City of New York Multivalent ras binding compounds
WO2015192343A1 (en) * 2014-06-18 2015-12-23 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences P53 activator small molecules
US9994577B2 (en) 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
EP3397254B1 (en) * 2015-12-31 2021-10-27 The Research Foundation for The State University of New York Tryptamine-based ship inhibitors for the treatment of cancer
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10918650B2 (en) * 2016-06-02 2021-02-16 University Of South Florida Method of treating melanoma using an inhibitor of an atypical protein kinase C
AU2017330443B2 (en) * 2016-09-26 2023-08-24 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN110291084A (zh) 2016-12-15 2019-09-27 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CN108251377B (zh) * 2018-01-16 2021-08-27 内蒙古大学 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法
US10738139B2 (en) 2018-12-18 2020-08-11 Itaconix Corporation Decarboxylation and amidation of polyitaconic acid polymers
KR102620902B1 (ko) * 2020-04-24 2024-01-04 가천대학교 산학협력단 신규 알파-시누클레인 방사성 리간드 및 이를 포함하는 신경퇴행성 질환 진단용 조성물
KR102428024B1 (ko) * 2020-06-11 2022-08-03 충북대학교 산학협력단 프로카스파제-3의 활성화제로서 신규한 (e)-n-아릴리덴-1-(4-클로로벤질)-1h-인돌-3-카보하이드라지드 및 이를 유효성분으로 포함하는 항암제 조성물
KR102617885B1 (ko) * 2021-05-07 2023-12-27 충북대학교 산학협력단 신규한 (e)-n'-((1-(4-클로로벤질)-1h-인돌-3-일)메틸렌)-2-(4-옥소퀴나졸린-3(4h)-일)아세토히드라지드 화합물 및 이를 유효성분으로 포함하는 항암제 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610722B2 (en) * 2000-04-10 2003-08-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20040138255A1 (en) * 1999-08-27 2004-07-15 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatease inhibitors
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US20050203162A1 (en) * 2004-03-12 2005-09-15 Miikana Therapeutics Corporation Cytotoxic agents and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US20010007877A1 (en) 1998-12-16 2001-07-12 George O. Burton Novel anti-infectives
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
EP1484329A1 (de) 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
JP4878285B2 (ja) 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138255A1 (en) * 1999-08-27 2004-07-15 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatease inhibitors
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US6610722B2 (en) * 2000-04-10 2003-08-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20050203162A1 (en) * 2004-03-12 2005-09-15 Miikana Therapeutics Corporation Cytotoxic agents and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Samuals, I. et al. Journal Cellular Biochemistry, 2001, vol.82 no 3 p452-66 *

Also Published As

Publication number Publication date
WO2007062399A2 (en) 2007-05-31
WO2007062399A3 (en) 2007-12-21
CN101360422B (zh) 2013-10-23
EP1956910A2 (en) 2008-08-20
AU2006318212A1 (en) 2007-05-31
EP1956910A4 (en) 2010-03-24
US20090286847A1 (en) 2009-11-19
CA2631082A1 (en) 2007-05-31
CN101360422A (zh) 2009-02-04
US8883841B2 (en) 2014-11-11
EP1956910B1 (en) 2014-09-17
JP5460054B2 (ja) 2014-04-02
AU2006318212B2 (en) 2012-01-12
RU2448703C2 (ru) 2012-04-27
CA2631082C (en) 2015-02-03
RU2008125065A (ru) 2009-12-27
JP2009517401A (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
AU2006318212B2 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
JP6389884B2 (ja) 癌を治療するための方法及び組成物
JP4989976B2 (ja) 翻訳開始阻害剤としての3−3−二置換オキシインドール
US8771754B2 (en) Use of GSK3 inhibitors in combination with radiation therapies
JP2025128193A (ja) Pcna阻害剤
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
CN111479570A (zh) 用于治疗与dux4表达相关的疾病的化合物
CA2995374A1 (en) Mechanism of resistance to bet bromodomain inhibitors
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
JP7138975B2 (ja) 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法
WO2025157286A1 (zh) 包含prmt5抑制剂和mat2a抑制剂的药物组合物
WO2025157284A1 (zh) 包含prmt5抑制剂和化疗剂的药物组合物
EP3397254B1 (en) Tryptamine-based ship inhibitors for the treatment of cancer
WO2014048377A1 (zh) 治疗肿瘤的组合药物及其应用
US6495586B2 (en) Scytonemin and methods of using thereof
EP4601654A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones
JP2025517442A (ja) Teadを標的とする化合物およびその方法
CN109939116A (zh) Rock2抑制剂在制备药物中的用途
EP3624798A1 (en) Methods and pharmaceutical compositions for the treatment of mast cell diseases
BR112015016433B1 (pt) Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT( S) FILED 20 MAR 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAR 2012

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired